Src

  • Compare Src Products
  • Research Area

Src Inhibitors (9)

water-soluble

Cat.No. Product Name Information Product Citations Customer Reviews
S1021 Dasatinib Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
  • Cell Stem Cell, 2012, 10(2):210-7
  • Cancer Discov, 2011, 1(7):608-25
  • J Exp Med, 2013, 210(11):2205-21
S1006 Saracatinib (AZD0530) Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.
  • Nat Cell Biol, 2013, 15(4):395-405
  • Nat Cell Biol, 2014, 16(5):401-14
  • The Journal of Clinical Investigation, 2014, 124(7):3003-15
S1014 Bosutinib (SKI-606) Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
  • Blood, 2011, 118(7):1885-98
  • Cancer Res, 2010, 70(19):7489-99
  • Mol Cell Biol, 2012, 32(2):320-32
S2700 KX2-391 KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
S7008 PP2 PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
S7565 WH-4-023 WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2nM and 6 nM, respectively.
S2202 NVP-BHG712 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
  • Anticancer Res, 2014, 34(6):2913-8
S7060 PP1 PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
S2391 Quercetin Quercetin, a natural flavonoid present in vegetables, fruit and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM.
Tags: Src activation | Src kinase family | Src family kinases | Src activity | Src cancer | Src tyrosine kinase | Src pathway | Src phosphorylation | Src inhibition | Src kinase pathway | Src kinase assay | Src inhibitors cancer | Src inhibitor clinical trials | Src inhibitor review
Contact Us